IA-WORKIVA
20.10.2021 14:02:05 CEST | Business Wire | Press release
Workiva Inc. (NYSE:WK), the company that simplifies complex work, announced the winners of the 2021 Workiva Partner of the Year Awards. The awards recognize partners that have leveraged their significant industry and solution-specific experience to help customers expand their use of the Workiva platform to drive transparency in reporting and compliance. Award recipients were recognized during the Company’s virtual Global Partner Summit , held October 18 & 19.
“Our partners are instrumental in deploying the Workiva platform as a critical component in digital transformations across global enterprises,” said Corey Wells, vice president of partnerships and alliances at Workiva. “It’s an honor to recognize this year’s winners for helping drive the innovation and collaboration that has made a lasting impact on our customers' business.”
2021 Partner of the Year Award Winners
- Global Partner of the Year - Deloitte
- Global Technology Partner of the Year - FloQast
- North American Advisory Partner of the Year - PwC US
- North American Mid-Market Advisory Partner of the Year - Clearview Group
- North American Emerging Partner of the Year - DHG
- EMEA Partner of the Year - PwC Germany
- EMEA Emerging Partner of the Year - Advance Tax Compliance
- APAC Partner of the Year - PwC Hong Kong , PwC Japan , and PwC Taiwan
- Partner Innovation Award Winner - F.H. Black
More about the 2021 Partner of the Year Award Winners
Advance Tax Compliance (ATC) delivers high-quality implementations and supports the Workiva sales team with new clients. ATC is also an active contributor to Workiva marketing events, client demos and the Workiva Marketplace.
Clearview Group * has been named the North American Mid-Market Advisory Partner of the Year two years in a row. Clearview Group has a masterful understanding of Workiva solutions and delivers a compelling value story. Clearview Group has grown with Workiva, from supporting integrated risk management to developing a comprehensive service line, delivering advisory and transformation services powered by collaboration across management reporting, and financial reporting as well.
Deloitte * has been named global partner of the year two years in a row. Deloitte collaborates globally with Workiva, introducing the company to new customers, identifying new use cases and supporting sales teams. Deloitte has been instrumental in communicating the value of the Workiva platform and helping global customers use innovative technology to help address complex business problems.
DHG , a top 20 public accounting, tax, and advisory firm, helped bring Workiva’s Global Statutory Reporting (GSR) and Environmental, Social, and Governance (ESG) offerings to market. DHG’s global teams work across EMEA and North America with Workiva to help joint customers, which include some of the largest companies in the world, navigate the complexities of GSR and ESG reporting.
F.H. Black * is a groundbreaking services partner that has elevated and extended the most technically advanced aspects of the Workiva platform. F.H. Black's innovative methodology and investment into collaborating with the Workiva product teams have helped tailor Workiva’s solutions for the public sector, specifically the development of Government Finance Officers Association (GFOA) compliant financial reports, budget books, Governmental Accounting Standards Board (GASB) 87 solutions and State-mandated solutions.
FloQast * has won the Global Technology Partner of the Year award two years in a row. FloQast continues to bring extreme value to Workiva and their joint customers with their accounting workflow automation solution. FloQast also invested in developing a direct API into the Workiva platform to provide joint customers increased visibility of the Close to Report process that spans the Finance, Accounting and Reporting teams.
PwC* has a dedicated alliance team with a depth of experience that helps strengthen Workiva's global position as a strategic platform for businesses. PwC collaborates with Workiva globally across all use cases and seeks opportunities to embed Workiva into PwC tech-enabled offerings. PwC continually invests and grows their Workiva-focused resources and is dedicated to accelerating the success of Workiva and their shared, global customers. PwC was recognized for three regional awards: North American Partner of the Year (PwC US), EMEA Partner of the Year (PwC Germany), and APAC Partner of the Year (PwC Hong Kong, PwC Japan, and PwC Taiwan).
*Denotes Workiva Marketplace Innovator. Marketplace Innovators played a crucial role in the launch of the Workiva Marketplace by contributing meaningful templates, services and content that were readily available for customers to add to their workspaces and use upon the launch of the marketplace in August, 2021.
About Workiva
Workiva Inc. (NYSE: WK) simplifies complex work for thousands of organizations worldwide. Customers trust Workiva’s open, intelligent and intuitive platform to connect data, documents and teams. The results: improved efficiency, greater transparency and less risk. Learn more at workiva.com .
Read the Workiva blog: www.workiva.com/blog
Follow Workiva on LinkedIn: www.linkedin.com/company/workiva
Like Workiva on Facebook: www.facebook.com/workiva/
Follow Workiva on Twitter: www.twitter.com/Workiva
Follow Workiva on Instagram: www.instagram.com/workivalife
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005117/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom